With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this time going after the KRAS pathway with a global deal that could bring Kumquat ...

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Stocks: European stocks largely ticked upward, gaining ground on Monday's close, as investors awaited inflation data from the U.S. and expected insight from Germany ...

Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

Novartis's Ianalumab Meets Goals in Phase 3 Trials to Treat Primary Immune Thrombocytopenia Novartis said its ianalumab drug combined with eltrombopag met the primary endpoint in a late-stage trial, ...